Cholangiocarcinoma — Trials

Cholangiocarcinoma — Trials · CancerIndex

Clinical trials

Registered studies

760 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 210
Recruiting: 120
Ph III recruiting: 7
Growth YoY: +17.4%
Industry share: 15%
Top sponsor: National Cancer Institute (NCI)
Termination share: 36.6%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (106)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04087876	Expanded Access Use of Derazantinib for Advanced Intrahepatic Cholangiocarcinoma (iCCA) With FGFR Genomic Alterations	no longer available	—	—	Basilea PharmaceuticaINDUSTRY	0	Apr 6, 2025	clinicaltrials
NCT03414489	Expanded Access for the Treatment of Advanced Cholangiocarcinoma With ABC294640 (Yeliva ®)	no longer available	—	—	RedHill Biopharma LimitedINDUSTRY	0	Mar 18, 2025